As filed with the Securities and Exchange Commission on February 1, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Translation of Registrant's na ...

Novartis(NVS) - 2022 Q4 - Annual Report ...

Novartis AG (NYSE:NVS) 41st Annual J.P. Morgan Healthcare Conference Call January 9, 2023 11:15 AM ET Company Participants Vasant Narasimhan - Chief Executive Officer Conference Call Participants Richard Vosser - JPMorgan Chase & Co. Richard Vosser Welcome to the Novartis presentation at the 41st JPMorgan Healthcare Conference. I'm Richard Vosser, European pharma analyst at JPMorgan. It's my great pleasure to introduce Vas Narasimhan, the CEO of Novartis. Before I hand over to him for his presentation, I'd ...

Company overview Financial review 2022 priorities Appendix References 1 Investor Relations │ Q3 2022 Results û Q3 2022 Results Investor presentation U NOVARTIS | Reimagining Medicine Company overview Financial review 2022 priorities Appendix References 2 NOVARTIS Q3 RESULTS | OCTOBER 25, 2022 | NOVARTIS INVESTOR PRESENTATION Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identifi ...

Novartis AG (NYSE:NVS) Q3 2022 Earnings Conference Call October 25, 2022 8:00 AM ET Company Participants Samir Shah - Global Head, Investor Relations Vasant Narasimhan - Chief Executive Officer Harry Kirsch - Chief Financial Officer Conference Call Participants Graham Parry - Bank of America Wimal Kapadia - Bernstein Richard Parkes - BNP Paribas Emmanuel Papadakis - Deutsche Bank Matthew Weston - Credit Suisse Simon Baker - Redburn Richard Wagner - Wolfe Research Stephen Scala - Cowen Kerry Holford - Berenb ...

Novartis AG (NYSE:NVS) Q2 2022 Results Conference Call July 19, 2022 8:00 AM ET Company Participants Samir Shah - Global Head, IR Vas Narasimhan - CEO Harry Kirsch - CFO Conference Call Participants Matthew Weston - Credit Suisse Tim Anderson - Wolfe Research Richard Vosser - JP Morgan Emmanuel Papadakis - Deutsche Bank Graham Parry - Bank of America Steve Scala - Cowen Florent Cespedes - Société Générale Emily Field - Barclays Simon Baker - Redburn Kerry Holford - Berenberg Seamus Fernandez - Guggenheim Se ...

Company overview Financial review 2022 priorities Appendix References 1 Investor Relations │ Q2 2022 Results 台 Q2 2022 Results Investor presentation U NOVARTIS | Reimagining Medicine Company overview Financial review 2022 priorities Appendix References 2 NOVARTIS Q2 RESULTS | JULY 19, 2022 | NOVARTIS INVESTOR PRESENTATION Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified ...

Novartis AG (NYSE:NVS) Q1 2022 Earnings Conference Call April 26, 2022 8:00 AM ET Company Participants Samir Shah - Global Head, Investor Relations Vasant Narasimhan - Chief Executive Officer Harry Kirsch - Chief Financial Officer Conference Call Participants Graham Parry - Bank of America Simon Baker - Redburn Matthew Weston - Credit Suisse Wimal Kapadia - Bernstein Andrew Baum - Citi Richard Vosser - JPMorgan Emmanuel Papadakis - Deutsche Bank Emily Field - Barclays Tim Anderson - Wolfe Research Peter Wel ...

Company overview Financial review 2022 priorities Appendix References 1 Investor Relations │ Q1 2022 Results f Q1 2022 Results Investor presentation U NOVARTIS | Reimagining Medicine Company overview Financial review 2022 priorities Appendix References 2 NOVARTIS Q1 RESULTS | APRIL 26, 2022 | NOVARTIS INVESTOR PRESENTATION Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified ...

Novartis Investor Relations Novartis New Organizational Model Powering our next phase of innovation, growth, and productivity Investor presentation April 04, 2022 Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as "potential," "expected," "will," "planned," "pipeline," "outlook," or similar expressions, or by express or implied discussions regarding our ne ...